BowFlex Inc. ("BowFlex" or "the Company") today announced that the U.S. Bankruptcy Court for the District of New Jersey (the "Court") entered an order approving the sale of the Acquired Assets pursuant to the terms of the previously announced Stalking Horse Asset Purchase Agreement ("Purchase Agreement") with Johnson Health Tech Retail, Inc. ("Johnson Health Tech" and such order, the "Sale Order"). Pursuant to the terms of the Purchase Agreement, Johnson Health Tech has agreed to acquire substantially all of the Company's assets (the "Acquired Assets") for $37,500,000 in cash, less certain adjustments. "We are pleased that the Court has approved this transaction with Johnson Health Tech,"

Secured Commitment for $25 Million in Debtor-in-Possession Financing to Continue to Fulfill Customer Orders and Support Ordinary Course Operations BowFlex Inc. (NYSE:BFX) ("BowFlex" or "the Company") today announced that it has entered into a purchase agreement with Johnson Health Tech Retail, Inc. (the "Stalking Horse Bidder") to serve as the stalking horse bidder to acquire substantially all of the assets of the Company for $37,500,000 in cash at the closing of the transaction, less closing adjustment amounts for accounts receivable, inventory and certain transfer taxes. In order to facilitate the sale process, the Company and certain of its subsidiaries have voluntarily initiated a Cha

BowFlex Inc. (NYSE:BFX) received written notice on November 27, 2023, from the New York Stock Exchange (NYSE) that the Company is not in compliance with the NYSE continued listing standards, which require it to maintain an average global market capitalization of at least $50.0 million over a consecutive 30-day trading period and, at the same time, a total stockholders' equity equal to or greater than $50.0 million. The Company plans to notify the NYSE by December 11, 2023 of its receipt of the notice and that it intends to submit a plan to cure the global market capitalization listing standard deficiency. The NYSE provides a period of 45 days from receipt of the notice to submit a plan

Direct Segment Net Sales of $21 Million Down 15% versus Q2 Fiscal 2023 Direct Strength Product Sales Up 15% versus Q2 Fiscal 2023 Reaches 596K JRNY® Members During Q2 Fiscal 2024, Up 51% versus Q2 Fiscal 2023 Adjusted EBITDA Loss Reduced by 41% versus Q2 Fiscal 2023 Updates Fiscal Year 2024 Guidance BowFlex Inc. (NYSE:BFX) today reported its unaudited operating results for the fiscal 2024 second quarter ended September 30, 2023. Management Comments "The retail environment has remained challenging throughout our fiscal year second quarter. We continued to offset the topline softness with diligent cost management and operational excellence efforts, resulting in another quarter o

BowFlex Inc. (NYSE:BFX) (the "Company") today announced that the Company will report its financial results for the fiscal second quarter ended September 30, 2023 after the market closes on November 14, 2023, followed by a management hosted conference call to discuss the Company's operating results. The live conference call and webcast is scheduled for 1:30 p.m. PT (4:30 p.m. ET) on Tuesday, November 14, 2023. The conference call can be accessed by calling (877) 425-9470 in North America and International callers may dial (201) 389-0878. Additionally, there will be presentation slides accompanying the earnings call. The slides will be displayed live on the webcast and will be available to

15F-12B - BOWFLEX INC. (0001078207) (Filer)

8-K - BOWFLEX INC. (0001078207) (Filer)

8-K - BOWFLEX INC. (0001078207) (Filer)

EFFECT - BOWFLEX INC. (0001078207) (Filer)

S-8 POS - BOWFLEX INC. (0001078207) (Filer)

S-8 POS - BOWFLEX INC. (0001078207) (Filer)

S-8 POS - BOWFLEX INC. (0001078207) (Filer)

S-8 POS - BOWFLEX INC. (0001078207) (Filer)

S-8 POS - BOWFLEX INC. (0001078207) (Filer)

S-8 POS - BOWFLEX INC. (0001078207) (Filer)